)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
NextCell Pharma
NextCell Pharma (NXTCL) investor relations material
NextCell Pharma Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary28 May, 2026
Executive summary
Operating income for Q1 2026 was SEK 2.8 million, down from SEK 3.4 million year-over-year.
Net income for Q1 2026 was SEK -10.4 million, compared to SEK -7.6 million in Q1 2025.
Cash and cash equivalents increased to SEK 32.3 million from SEK 22.1 million year-over-year, supported by a SEK 15 million directed share issue.
Strategic focus on international expansion, platform development, and commercialization of cell therapy for type 1 diabetes.
Financial highlights
Net sales for Q1 2026 were SEK 2.7 million, with Cellaviva contributing SEK 2.6 million.
Operating loss increased to SEK -10.5 million from SEK -7.8 million year-over-year.
Earnings per share improved to SEK -0.08 from SEK -0.10 year-over-year.
Equity ratio was 78% at quarter-end, down from 85% a year earlier.
Total cash flow for Q1 2026 was SEK 6.3 million, compared to SEK -10.6 million in Q1 2025.
Outlook and guidance
Focus on commercial execution of the type 1 diabetes program and scaling manufacturing capabilities.
Anticipated release of one- and two-year clinical data for ProTrans-Young study after summer 2026.
Long-term strategy includes expanding the clinical pipeline and achieving positive operating cash flow.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NextCell Pharma
- ProTrans clinical progress, international expansion, and stable liquidity highlight the period.NXTCL
Transition period26 Feb 2026 - ProTrans-Young shows strong safety but unclear efficacy after one year; long-term data awaited.NXTCLStudy Result24 Nov 2025
- ProTrans shows durable efficacy in diabetes, with global expansion and new indications ahead.NXTCLLife Science Summit 202519 Nov 2025
- Losses narrowed and revenues grew as clinical and operational milestones were reached.NXTCLQ4 202530 Oct 2025
- Net loss narrowed year-over-year as funding and partnerships strengthened clinical progress.NXTCLQ3 202524 Jul 2025
- ProTrans clinical progress and successful capital raise position NextCell for future growth.NXTCLQ4 202413 Jun 2025
- Rights issue oversubscribed, raising SEK 40.1M to fund ProTrans trials and operations.NXTCLQ3 202413 Jun 2025
- ProTrans advances in diabetes, Cellaviva and QVance drive growth, losses narrow.NXTCLQ1 20255 Jun 2025
- ProTrans advances, Cellaviva hits record sales, and QVance gains traction amid financial improvement.NXTCLQ2 20255 Jun 2025
Next NextCell Pharma earnings date
Q2 202627 Aug, 2026
NextCell Pharma
Next NextCell Pharma earnings date
Q2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage